Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Variant-Adapted BNT162b2 Vaccine in Healthy Children
NCT05543616Phase 3Completed
- Sponsor
- BioNTech SE
- Start
- Sep 2022
- Primary completion
- Jul 2026
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 5
01
Overview
Phase 3, randomised trial of tozinameran in coronavirus disease 2019 (COVID-19) (23 arms), sponsored by BioNTech SE. Primary endpoints: Percentage of participants reporting local reactions, Percentage of participants reporting systemic events and 4 more. Started Sep 2022; status: completed.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05543616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05543616.